Pharmaceutical Industry
Articles tagged with Pharmaceutical Industry
Chinese Medical Journal article review explores organoid models in investigational new drug regulation and development
How AI can help us count the ‘good’ viruses used in biopharmaceuticals
Researchers developed an AI-powered methodology to identify and count target viruses more efficiently than previous techniques. The new approach uses electrochemical impedance spectroscopy and machine learning to separate signals from noise, enabling quick and accurate readings across a wide range of titers.
Digital Science introduces Compass by Dimensions to transform medical affairs publication insights
Compass combines Dimensions citation data and Altmetric attention metrics in a single platform, providing real-time publication intelligence. This solution addresses the fragmented data challenge faced by medical affairs teams, enabling them to make informed strategic decisions and communicate impact more effectively.
Alliance study shows new promise against locally advanced lung cancer
A study by the Alliance Foundation Trials shows that combining immunotherapy and chemotherapy before surgery can help more patients with locally advanced non-small cell lung cancer undergo complete cancer resection, improving their long-term health. The treatment also led to high rates of lymph node clearance and successful surgical re...
Clinical trial aims to address vaginal complaints after breast cancer diagnosis
A clinical trial aims to evaluate whether laser therapy reduces vaginal dryness caused by breast cancer treatment. The study, REVITALIZE, plans to enroll approximately 250 women with a history of breast cancer who experience moderate to severe vaginal dryness.
OYE Therapeutics achieves first patient first dose in 505(b)(2) bridging study
OYE-101, a novel intravenous caffeine formulation, has been developed to accelerate recovery from general anesthesia and deep sedation. The company's lead program is being evaluated in a scientific bridging study to support a 505(b)(2) NDA for OYE-101.
Alliance marks Adolescent and Young Adult Cancer Awareness Week
The Alliance for Clinical Trials in Oncology is enrolling adolescent and young adult cancer patients in various trials, including genetic services and treatment studies. These trials aim to address longstanding gaps in care and improve outcomes for AYAs with cancer.
Registrations open for São Paulo School of Advanced Science on Regulatory Governance
The São Paulo School of Advanced Science on Regulatory Governance explores emerging regulatory frontiers in Latin America. The program features speakers from leading international institutions and offers a range of activities, including flash talks, poster presentations, and paper development workshops.
Advertising payments to news websites that publish health misinformation
Between 2021 and 2024, government organizations accounted for around one-tenth of the estimated $336 million spent on advertising to news websites publishing health misinformation. Pharmaceutical companies also made notable contributions.
City St George’s partners with Paradigm Biopharmaceuticals to investigate mechanism of osteoarthritis pain drug candidate
City St George's, University of London, is partnering with Paradigm Biopharmaceuticals to test a potential treatment for osteoarthritis. The partnership aims to investigate the mechanism of action of pentosan polysulfate sodium (iPPS) on bone marrow lesions, which are linked to pain in osteoarthritis.
AstraZeneca joins Robert A. Winn Excellence in Clinical Trials Award Program as Funding Partner
The Robert A. Winn Excellence in Clinical Trials Award Program has partnered with AstraZeneca to support five medical students participating in the Winn Clinical Investigator Pathway Program (Winn CIPP). The program provides immersive training, mentorship, and hands-on experience to prepare students for careers in clinical research.
Damon Runyon scientists gather for 2026 Accelerating Cancer Cures Symposium
The Accelerating Cancer Cures Research Symposium brings together Damon Runyon scientists and industry partners to foster communication and collaboration. The symposium features updates on research aimed at developing more precise targeted therapies for cancer treatment.
Over the past decade, early-stage drug innovation shifted toward China, Georgetown researchers find
Early-stage drug development worldwide has nearly doubled over the past decade, with China's share increasing from 8% to 32%, according to Georgetown University researchers. The number of early-stage programs increased by 82.4% from 10,417 in 2015 to 18,999 in 2024.
Geographic shifts in early-stage biopharmaceutical innovation
Early-stage drug development has nearly doubled globally over the past decade, driven by a shift from a US-dominated system to a two-hub structure. This change may have implications for scientific workforce development, investment, and patient access to new therapies.
NRG Oncology/Alliance trial finds immunotherapy did not improve survival when added to chemoradiotherapy for small cell lung cancer
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Alliance trial aims to improve outcomes for chronic lymphocytic leukemia
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Upcoming Alliance webinar highlights latest cancer treatment advances
The Alliance for Clinical Trials in Oncology will host a webinar highlighting recent clinical advances in breast cancer, multiple myeloma, and leukemia. Researchers will present key findings from ASH and SABCS meetings, impacting treatment outcomes.
New Study: Cybersecurity isn’t just a safeguard — it can help businesses perform better
A new study by Binghamton University School of Management reveals that businesses can improve their performance when they openly discuss and address cybersecurity issues. The research found a positive correlation between cybersecurity readiness and firm performance, suggesting that proactive measures can lead to better outcomes.
Timing is everything. Why the US gets some drugs faster than other countries
A new study led by Brown University researchers challenges the assumption that US access to new medicines is driven by faster government review. The study found that companies submit lower-value drugs earlier in the US than in other high-income countries, giving Americans earlier access to expensive medications with limited medical ben...
Study: New class of catalysts could dramatically change playing field in nickel catalysis
Researchers at the University of Illinois Urbana-Champaign have developed a new method for synthesizing thermally stable Ni(I) compounds that opens new avenues for building complex molecules. The new catalysts exhibit rapid ligand substitution, exceptional performance in key reactions, and chemo-selectivity.
Revenues from drugs subject to price reduction under Inflation Reduction Act are not essential for R&D or normal returns on investment
Research from Bentley University's Center for Integration of Science and Industry shows public companies with price negotiable drugs under IRA were more profitable than comparable companies in the S&P500. The study also found that revenues from these drugs exceeded normal returns on investment before price negotiations began.
Targeted therapy shows promise against aggressive brain tumors, alliance trial finds
A national clinical trial found that abemaciclib, an oral cancer drug, may slow tumor growth in patients with aggressive meningiomas with specific genetic mutations. The trial showed promising results, with a median progression-free survival of 10 months and a median overall survival of 29 months.
Public views about opioid overdose and people with opioid use disorder
A 2025 survey found that U.S. adults view opioid overdose as a serious problem, with differing opinions on who is responsible for reducing overdose rates. The study suggests varying preferences for future actions to address overdose among conservatives, moderates, and liberals.
New alliance trial seeks to reduce delays in gastrointestinal cancer treatment
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
BGI Genomics marks 15 years with 2025 European Partnership Summit in Budapest
BGI Genomics convened its 2025 European Partnership & Networking Summit in Budapest, fostering innovation, collaboration, and growth. The event introduced its comprehensive NGS solution, Gensiro, integrating AI and automation to streamline laboratory workflows.
Behind the 2025 “shroom boom” hides a bad trip
The article highlights the mismatch between psychedelics and economic drug development principles. Pharmaceutical companies are developing short-acting compounds and neuroplastogens to engineer trips out of the experience altogether. Dr. Sandy Hager's research suggests investors should remain cautious due to weak intellectual property ...
Obesity drugs improve heart health: Study shows additional benefits of semaglutide and tirzepatide
Researchers analyzed insurance claims data from US health insurers to demonstrate the cardiovascular benefits of semaglutide and tirzepatide. Both GLP-1 drugs provide cardioprotective effects, reducing the risk of stroke and heart attack by 18% and 13%, respectively.
UniSA leads national pilot to improve medication safety in aged care
A new national quality framework has been developed to evaluate medication management and clinical services provided by pharmacists in residential aged care. The PHARMA-Care National Quality Framework promotes a transparent, person-centred approach to medication management, aiming to reduce risks linked to polypharmacy.
IU Kelley Futurecast: AI and energy infrastructure may buoy US economy in 2026
The US economy is expected to grow at 1.8% in 2026, with AI and energy infrastructure investments playing a key role. Despite this, job creation will not be strong enough to keep unemployment rates from rising to 4.8%, with the nation's economy facing uncertainty around trade policy.
GLP-1 drugs effective for weight loss, but more independent studies needed
Three new Cochrane reviews found GLP-1 drugs result in clinically meaningful weight loss, but evidence on longer-term outcomes and side effects is limited. The wider use of these drugs should consider social and commercial determinants to avoid deepening existing health inequities.
Light-based tool continuously monitors vaccine quality during production
A new analytical tool using Raman spectroscopy enables rapid monitoring of vaccine quality and quantity, with results in 30 seconds or less. The tool operates on the production line, saving time and money in vaccine production.
Science/Science Careers’ Survey ranks top biotech, biopharma, and pharma employers
The Science/Science Careers' 2025 Top Employers Survey ranked the top companies in biotechnology, biopharmaceuticals, and pharmaceuticals based on employee responses. The survey found that companies with strong reputations as employers prioritized innovation, leadership, and work culture.
A potential game-changer: Mizzou researcher creating a new way to treat genetic disorders
A new RNA-based therapy targeting Marfan syndrome shows promise in treating the genetic disorder, which can lead to aortic aneurysms and be fatal. The therapy, developed by Mizzou researcher Dunpeng Cai, aims to correct mutated RNA for those with Marfan syndrome.
Could direct-to-consumer drug pricing compete with prescription insurance?
A new study shows that direct-to-consumer pharmacy pricing can offer lower total costs (431% lower) compared to commercial pharmacies for insured patients. Out-of-pocket neurologic drug costs are 75% higher, but most medications cost less than $635 per year.
Wastewater treatment plants are a major source of pharmaceutical pollution
Conventional treatment methods used by municipal wastewater treatment facilities are ineffective at removing common pharmaceuticals like Prozac, fluoxetine, and loratadine from wastewater. These drugs are discharged into lakes, rivers, and streams, posing risks to aquatic organisms.
Taking the guesswork out of concussion assessments
A portable device using machine learning can detect signs of concussions in real-time, providing a more objective way to assess injuries. The Mizzou Point-of-Care Assessment System combines a force plate, depth camera and interface board to track movement, balance and reaction times.
Towards pharmaceutical super intelligence: During BioHK 2025, Insilico Medicine gathers industry leaders to shape the future of AI in healthcare
The global market for AI in pharmaceuticals is projected to reach $13.4 billion by 2035, driven by Insilico Medicine's innovative use of generative AI. The company will share its achievements at a satellite forum during BIOHK2025, showcasing significant efficiency boosts compared to traditional methods.
Most US neurologists prescribing MS drugs have received pharma industry cash
A study of Medicare database payments found that nearly 80% of US neurologists prescribing multiple sclerosis (MS) drugs received industry payments, with higher volume prescribers more likely to be beneficiaries. Recipients were also more likely to prescribe the company's drugs, especially if payments were larger and sustained.
Threats of weather disasters for drug manufacturing facilities in the US
Climate-related disasters pose significant disruptions to US drug manufacturing facilities, affecting nearly two-thirds of production sites. Researchers assessed the impact of disaster events on counties with US drug production facilities and found that nearly two-thirds were located in areas affected by at least one disaster declaration.
‘Controlled evolution’ dramatically boosts pDNA production for biomedical manufacturing
Researchers at North Carolina State University have developed a controlled evolution technique that dramatically increases plasmid DNA (pDNA) production in E. coli bacteria. This breakthrough could significantly reduce the cost of gene therapies and expedite research, making pDNA resources more accessible.
Bentham Science publishes definitive guide on zebrafish in pharmacological research
The new handbook provides a practical approach to harnessing zebrafish as a model organism for biomedical research, covering drug efficacy evaluation and disease mechanisms. It offers step-by-step experimental protocols and theoretical grounding for researchers of all levels.
Advanced computing solutions for healthcare
The book explores innovative computing technologies transforming healthcare delivery, diagnostics, and monitoring. It covers topics like artificial intelligence, machine learning, IoT, wearable devices, and real-time communication systems.
JMIR Medical Informatics invites submissions on ambient AI scribes and AI-driven documentation technologies
The journal is seeking original research, viewpoints, and tutorials exploring the use of AI-driven documentation in clinical settings. Submissions should address practical applications, challenges, and future directions of AI-facilitated clinical documentation.
New gene therapy delivery device could let hospitals create personalized nanomedicines on-demand
A new gene therapy delivery device called NANOSPRESSO could revolutionize how hospitals treat rare diseases by allowing them to create personalized nanomedicines in-house. This democratized approach to precision medicine could boost access to low-cost bespoke gene and RNA therapies, especially in low-resource settings.
New nanoparticles offer safer, more effective drug delivery
Scientists at Xi'an Jiaotong-Liverpool University developed a new nanoparticle capable of carrying high doses of chemotherapy drugs while staying stable for extended periods. This innovation could make treatments more effective and reduce side effects.
New insights into migraine-related light sensitivity
Scientists have identified a brain molecule called NEAT1 that appears to play a central role in triggering light sensitivity (photophobia) during migraines. By disrupting the normal balance of nerve signaling and pain regulation, NEAT1 makes nerves more sensitive to light.
New discovery about how acetaminophen works could improve understanding about pain relievers
Researchers at Indiana University discovered a new way acetaminophen targets pain by inhibiting an enzyme that produces endocannabinoids. Reduced levels of these compounds may lead to decreased pain relief, providing a potential target for designing safer pain medications.
UTA course gives pre-health students clinical edge
The University of Texas at Arlington offers pre-health students valuable hands-on experience through an innovative collaboration. Students in SCIE 4304 participate in immersive clinical simulation lab at the UTA Smart Hospital, developing rudimentary clinical skills and overcoming imposter syndrome.
Research explores how the EU can improve its regulatory framework to drive pharmaceutical innovation
A new study suggests that European member states must work together and provide better incentives to develop new medicines. The research highlights the need for faster approval times and stronger support for innovative drugs to attract leading pharmaceutical companies.
First microbes blast off testing production of food for space travel
Imperial scientists launched a miniature laboratory into Earth orbit to engineer microbes that can produce food, pharmaceuticals, fuel, and bioplastics in microgravity. This partnership aims to create environmentally friendly and affordable non-animal foods, reducing the cost of space travel.
NSF-funded research heads to the international space station on NASA's SpaceX CRS-32 mission
Three NSF-funded investigations are launching on NASA's SpaceX CRS-32 mission to ISS National Laboratory. Investigations aim to advance pharmaceutical manufacturing, develop new materials, and study active matter in microgravity environment.
Artful single-atom catalyst for sustainable chemical and pharmaceutical synthesis
Researchers created an anchoring-borrowing strategy to form artful single-atom catalysts, overcoming traditional oxidative addition steps in cross-coupling reactions. The new catalysts achieve high yields, excellent stability, and set a benchmark for turnover numbers.
Studies shows new class of antibiotic is effective in tackling MRSA
A new class of antibiotic has been shown to be effective in treating MRSA infections, with a daily dose of epidermicin NI01 demonstrating equal efficacy to the current standard of care. The findings justify further pre-clinical development and could lead to new gel-type therapies for skin infections.
Wiley releases updated Maurer, Meyer, Helfer, Weber: LC-HR-MS/MS Library of Drugs, Poisons and Their Metabolites Database
The updated Maurer, Meyer, Helfer, Weber: LC-HR-MS/MS Library contains over 5,500 mass spectra for parent drugs and poisons, along with their metabolites. This comprehensive dataset enables scientists to confidently identify unknown compounds and assess toxic substance risks.
Announcing Maxwell Biosciences as Tier 1 Sponsor of ARDD 2025
ARDD 2025 to feature Nobel laureates and pharmaceutical executives discussing latest advancements in aging research. Maxwell Biosciences will showcase its CLAROMER technology enhancing innate immune system, promoting healthy longevity.
Insilico Medicine secures $110 million Series E financing to advance AI-driven drug discovery innovation
Insilico Medicine has secured a $110 million Series E financing to accelerate the advancement of its AI-driven drug discovery pipeline and platform developments. The funds will focus on refining AI models and algorithms, as well as advancing clinical validation of its flagship candidate for idiopathic pulmonary fibrosis treatment.
High-tech startup CrySyst provides quality-by-control solutions for pharmaceutical, fine chemical industries
CrySyst's QbC framework addresses crystallization monitoring, modeling and control using research from Purdue University. The software provides guided experiment selection, semiautomated model development and reliable solutions to reduce time and material usage.
HMRI partners with Novartis (Aust & NZ) to supercharge heart health impact
Hunter Medical Research Institute has formed a memorandum of understanding with Novartis (Aust & NZ) to explore future research projects focused on improving cardiovascular health. The partnership aims to accelerate innovation and enhance patient care through collaborative research initiatives.
Engineering biological reaction crucibles to rapidly produce proteins
Biomedical engineers at Duke University have developed a new technique that traps together cellular machinery to increase protein production rates. This approach uses synthetic disordered proteins to form compartments called biological condensates, which enhance the rate of protein production by bringing together biomolecular machinery...